Chimerix initiates CMX001 Stage 2 clinical trial in stem cell transplant sufferers for CMV Chimerix.

Chimerix initiates CMX001 Stage 2 clinical trial in stem cell transplant sufferers for CMV Chimerix, Inc., a biotechnology company developing orally-obtainable antiviral therapeutics, today announced the initiation of a multi-center Phase 2 medical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus . CMX001 is definitely a broad-spectrum antiviral agent with demonstrated activity against double-stranded DNA viruses. Related StoriesKey protein controls stem cell properties that could make them useful in regenerative medicineShorter sufferers receive lung transplants at lower ratesPublic policy needed to reduce stem cell tourism, say specialists Morbidities and organ loss due to CMV have become a significant medical issue as the regularity of organ transplantation provides increased and new immunosuppressive regimes have already been introduced, stated George Painter, Ph.D., Chief and President Executive Officer.Traditionally, most individual education components are written at or above a 10th grade reading level, yet almost half of U.S. Adults have trouble understanding and acting on information that’s written above an 8th grade level, and only 12 % have proficient wellness literacy. In addition to this plain language overhaul, the text font used is particularly designed for readers with low vision. The collection contains brochures, booklets and downloadable handouts that cover the complete spectrum of eye health.